Number of shares and voting rights of ADOCIA as of October 31, 2021

0

Enter Wall Street with Street Insider Premium. Claim your 1-week free trial here.


LYON, France – (BUSINESS WIRE) – Regulatory news:

Pursuant to the provisions of article L. 233-8 II of the French Commercial Code and article 223-16 of the Stock Exchange Authority (Financial Markets Authority, or “AMF”) ADOCIA SA charter, a French company anonimous society (company), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris: ADOC) a clinical stage biopharmaceutical company focused on the treatment of diabetes, obesity and metabolic diseases with innovative formulations of approved protein, releases its total number of outstanding shares and voting rights as of October 31, 2021.

Month

Dated

Total number of

outstanding shares

Total number of

theoretical vote

straight (1)

Total number of

exercisable vote

straight (2)

October

10/31/2021

7,137,521

9,909,064

9 871 140

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as a basis for calculating the crossing of holding thresholds. In accordance with article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which the voting right is attached, including the shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case the shares held by the Company under a contract. liquidity.

About Adocia

Adocia is a clinical-stage biotechnology company specializing in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In diabetes, Adocia’s portfolio of injectable therapies is among the largest and most differentiated in the industry, with six clinical stage products and several preclinical products. The proprietary BioChaperone® technology platform is designed to improve the efficacy and / or safety of therapeutic proteins while facilitating their use by patients. Adocia personalizes BioChaperone® to each protein for a given application.

Adocia’s clinical pipeline includes five new formulations of insulin for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo) and two combinations of a mealtime insulin with an amylin analogue pramlintide (M1Pram and BioChaperone® LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.

Adocia’s preclinical pipeline includes bihormonal combinations for the treatment of diabetes: a combination of fast acting insulin analogues and pramlintide (BioChaperone® AsPram), a combination of insulin glargine and GLP receptor agonists -1 (BioChaperone® Glargine Liraglutide). In addition, there are two bi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® GluExe) and a combination of pramlintide and exenatide (PramExe).

Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on the development of a hydrogel scaffold for people with type 1 diabetes. The first patent application supporting this program has been filed.

Disclaimer

This press release contains certain forward-looking statements regarding Adocia and its business. These forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in these forward-looking statements will be made, as these estimates are subject to numerous risks, including those set forth in the “Risk Factors” section of the Universal Registration Document. that was filed. to the Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com), in particular the uncertainties related to research and development, future clinical data, analyzes and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or considered not to be material by Adocia to date. The occurrence of some or all of these risks could cause the actual results, financial conditions, performance or achievements of Adocia to differ materially from those mentioned in forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.

Adociates

Gerard Soula

CEO

contactinvestisseurs@adocia.com

Phone. : +33 4 72 610 610

www.adocia.com

MC Services SA

Adocia Press Relations Europe

Raimond Gabriel

Management partner

adocia@mc-services.eu

Phone. : +49 89 210 228 0

The Ruth group

Adocia Investor Relations United States

Brett Mermelstein

Senior account manager

bmermelstein@theruthgroup.com

Phone. : +1 267 639 0721

Source: ADOCIA

Share.

Comments are closed.